What's Happening?
Paradigm Health has announced a collaboration with the U.S. Food & Drug Administration (FDA) to advance a new model for accelerating clinical trial execution and regulatory review. This initiative utilizes Paradigm Health's technology-enabled Study Conduct
platform, which allows for real-time data review by the FDA. The model is currently operational in a Phase 2 and a Phase 1b trial, involving pharmaceutical companies Amgen and AstraZeneca. The collaboration aims to reduce monitoring burdens, data entry, and trial costs, thereby speeding up regulatory reviews and improving clinical trial efficiency in the U.S. The platform captures data from electronic health records and other sources, evaluates FDA-defined data points, and transmits critical signals to trial sponsors and the FDA.
Why It's Important?
This collaboration is significant as it represents a shift towards a real-time, continuous regulatory environment, which could transform the clinical trial landscape in the U.S. By modernizing the flow of information, the initiative aims to accelerate the delivery of innovative therapies to patients, making clinical trials more efficient and cost-effective. This could enhance the U.S.'s competitiveness in global clinical research and potentially lead to faster access to new treatments for patients. The collaboration aligns the interests of policymakers, pharmaceutical companies, and patients, aiming to streamline the drug development process.
